Lemaitre Vascular Inc (LMAT) Stock Price & Analysis
Lemaitre Vascular Inc (LMAT) fell 1.95% to USD 95.59 as of July 26, 2026 at 18:21 UTC, according to Nexqual real-time market data.
LMAT last closed at USD 97.49; the session ranged USD 95.28–100.59 on volume of 349,426 shares. Market capitalization is $2.18B, with a 52-week range of USD 79.01–118.01 (NGM). Source: Nexqual, July 26, 2026 at 18:21 UTC.
Key Statistics (as of July 26, 2026 at 18:21 UTC)
| Price | USD 95.59 |
|---|---|
| Change | ▼ 1.95% (down) |
| Previous Close | USD 97.49 |
| Open | USD 100.59 |
| Day Range | USD 95.28 – 100.59 |
| 52-Week Range | USD 79.01 – 118.01 |
| Volume | 349,426 shares |
| Market Cap | $2.18B |
| Exchange | NGM |
Technical Analysis (LMAT)
Nexqual's technical model rates LMAT "SELL" based on 2 bullish and 4 bearish signals across 125 daily candles, as of July 26, 2026 at 18:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.81 (neutral) |
| vs SMA50 | Below (USD 97.02) |
| MACD | 0.34 (positive) |
Analyst Ratings (LMAT)
Wall Street analysts rate LMAT "Buy" based on 8 analysts, with a mean price target of USD 118.75 (range USD 102–135), per Nexqual as of July 26, 2026 at 18:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 118.75 |
| High Target | USD 135 |
| Low Target | USD 102 |
| Buy / Hold / Sell | 5 / 4 / 0 |
Earnings (LMAT)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 0.81 |
| Revenue Estimate | $71.47M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.68 vs est 0.66 ▲ beat |
| 2025-12-31 | USD 0.68 vs est 0.66 ▲ beat |
| 2025-09-30 | USD 0.75 vs est 0.56 ▲ beat |
| 2025-06-30 | USD 0.6 vs est 0.57 ▲ beat |
Source: Nexqual, July 26, 2026 at 18:21 UTC.
Financials & Fundamentals (LMAT)
| Total Revenue | $256.28M |
|---|---|
| Revenue Growth (YoY) | +11.20% |
| Gross Margin | +71.33% |
| Operating Margin | +26.71% |
| Profit Margin | +24.35% |
| ROE | +16.55% |
| Debt / Equity | 46.68 |
| Current Ratio | 14.32 |
| Total Cash | $367.23M |
| Total Debt | $189.82M |
| Free Cash Flow | $53.27M |
Source: Nexqual, July 26, 2026 at 18:21 UTC.
Financial Health Score (LMAT)
Nexqual rates Lemaitre Vascular Inc's overall financial health "Solid" across five dimensions, as of July 26, 2026 at 18:21 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 71%, operating 27% |
| Balance Sheet | Strong — $367M cash vs $190M debt, net cash position |
| Cash Flow | Strong — FCF $53M, 21% margin |
| Efficiency | Solid — ROE 17%, ROA 7.2% |
Ownership (LMAT)
| Insider Ownership | +6.51% |
|---|---|
| Institutional Ownership | +100.22% |
| Shares Outstanding | 22.85M |
| Float | 21.27M |
| Short % of Float | +8.14% |
Source: Nexqual, July 26, 2026 at 18:21 UTC.
Leadership (LMAT)
Lemaitre Vascular Inc is led by George W. LeMaitre (age 60), Chairman & CEO, per Nexqual as of July 26, 2026 at 18:21 UTC.
| Chairman & CEO | George W. LeMaitre (age 60) |
|---|---|
| President & Director | David B. Roberts (age 61) |
| Chief Financial Officer | Dorian P. LeBlanc (age 50) |
| Senior Vice President of Operations | Trent G. Kamke (age 54) |
| Founder and Chairman of Scientific Advisory Board | George D. LeMaitre FACS (age 91) |
Major Backers & Investors (LMAT)
Notable institutional backers of Lemaitre Vascular Inc include Conestoga Capital Advisors, LLC, First Trust Advisors LP, First TRT Exch-Trd Fd. VI-First TRT SMID Cap Rising Dividend Achievers, according to Nexqual as of July 26, 2026 at 18:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Conestoga Capital Advisors, LLC | 6.46% |
| First Trust Advisors LP | 4.37% |
| First TRT Exch-Trd Fd. VI-First TRT SMID Cap Rising Dividend Achievers | 4.27% |
| Congress Asset Management Co | 4.22% |
| Conestoga Funds-Conestoga Small Cap Fund | 4.17% |
| Copeland Capital Management, LLC | 3.81% |
| Geneva Capital Management LLC | 3.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 21.49% |
| Vanguard Group | 10.35% |
| State Street | 3.75% |
Source: Nexqual, July 26, 2026 at 18:21 UTC.
From Lemaitre Vascular Inc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific.
- The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services.
- In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures.
- It markets its products through a direct sales force and distributors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATRC | AtriCure, Inc. | USD 35.04 | ▲ 4.53% |
| MMSI | Merit Medical Systems, Inc. | USD 74.32 | ▲ 1.66% |
| OFIX | Orthofix Medical Inc. | USD 11.25 | ▲ 2.09% |
| LIVN | LivaNova PLC | USD 78.19 | ▼ 0.1% |
| LKFN | Lakeland Financial Corporation | USD 61.11 | ▼ 0.33% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 18:21 UTC. This page is informational and not investment advice.